|
|
|
New “Antisense” Experimental Therapy
Clinical Trial Announced
A new experimental therapy using an approach known as antisense, in which a drug is designed to shut down the RNA (Ribonucleic acid) that is responsible for the production of disease-causing proteins, is being prepared for a clinical trial in people with a familial form of ALS later this year. The clinical trial follows research funded by The ALS Association through TREAT ALS (Translational Research Advancing Therapy for ALS), our research pipeline that funds and facilitates the development of treatments for ALS based on important laboratory findings.
>> Read full story
ALS Researcher Lisa S. Krivickas Passes Away of ALS
>> Read full story
The ALS Association Announces The Milton Safenowitz Post-Doctoral Fellowship for ALS Research Grants
>> Read full story
Neuralstem Receives FDA Approval
To Begin First ALS Stem Cell Trial
>> Read full article about stem cell trial
Scientists Discover Faster Protein Aggregation
Means Faster Disease Progression in ALS
>> Read full article about disease progression in ALS
See our Research News Archive
for a full list of ALS research news items.
|
|
|
|
 | ALS Research Overview |
|
Read The ALS Association's White Paper on the State of ALS Research.
|
|
| TREAT ALS |
|
Read about the new initiative to accelerate clinical trials through ALS Research.
|
|
| Meet The ALS Association's Chief Scientist |
|
| Research Grants |
|
Send us an email with your contact information if you would like to be added to our abstract call list.
|
|
|
